Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6526
    +0.0026 (+0.40%)
     

  • OIL

    82.73
    -0.08 (-0.10%)
     

  • GOLD

    2,337.60
    -0.80 (-0.03%)
     

  • Bitcoin AUD

    97,565.34
    -4,180.14 (-4.11%)
     

  • CMC Crypto 200

    1,359.97
    -22.60 (-1.63%)
     

  • AUD/EUR

    0.6081
    +0.0011 (+0.18%)
     

  • AUD/NZD

    1.0954
    +0.0012 (+0.11%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,093.05
    +52.67 (+0.66%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    17,981.18
    -107.52 (-0.59%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

Carlyle nears $4 bn deal for Johnson & Johson unit: WSJ

AFP
A person does a blood test at a roadside AIDS testing table in Langa, a suburb of Cape Town during the International AIDS Day on December 1, 2010

The Carlyle Group is in exclusive talks to buy Johnson & Johnson's blood-testing unit for $4 billion, The Wall Street Journal reported Tuesday.

A person familiar with the matter told AFP in September that Johnson & Johnson had previously sought to obtain $5 billion from the sale.

The Ortho Clinical Diagnostics unit specializes in making tests to determine a patient's blood type and screen for viruses such as HIV or hepatitis C. It also makes tests to diagnose a heart attack and determine heart damage.

Carlyle and a team of Blackstone Group and Danaher Corp have been competing to buy up the unit, according to the Journal.

ADVERTISEMENT

It said Johson & Johnson favored Carlyle, which hopes to put more than $1 billion in cash toward the deal.

The diagnostic testing market is estimated at $46 billion worldwide and grows six to seven percent a year, according to consultants Frost & Sullivan.